Earnings summaries and quarterly performance for Lifeloc Technologies.
Executive leadership at Lifeloc Technologies.
Board of directors at Lifeloc Technologies.
Research analysts covering Lifeloc Technologies.
Recent press releases and 8-K filings for LCTC.
Lifeloc Technologies, Inc. Reports Q3 2025 Results
LCTC
Earnings
Product Launch
New Projects/Investments
- Lifeloc Technologies, Inc. reported net revenue of $2.257 million for the third quarter of 2025, an 8% increase compared to the same period last year, but posted a net loss of $(263) thousand, or $(0.10) per diluted share.
- The company's gross margin for Q3 2025 decreased to 40.2% from 43.7% in Q3 2024, primarily due to general cost inflation and tariffs.
- The net loss for the quarter and year-to-date was largely attributed to high research and development costs associated with the commercialization of its SpinDetect™ centrifugal drug analyzer.
- Lifeloc is initiating beta testing for the SpinDetect™ oral-fluid analyzer, with a commercial launch anticipated in 2026, and is exploring broader applications of its microfluidic technology.
Nov 12, 2025, 10:18 PM
Lifeloc Technologies, Inc. Details Merger Consideration
LCTC
M&A
Takeover Bid
- Each share of Lifeloc Technologies, Inc. (LCTC) Common Stock will be converted into the right to receive 0.048 shares of Parent Common Stock at the effective time of the merger.
- As of the date of the agreement, 4,946,502 shares of LCTC Common Stock were issued and outstanding.
- The Parent company had 2,752,616 shares of Parent Common Stock issued and outstanding as of the date of the agreement.
Oct 14, 2025, 9:58 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more